Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited request for medical information.

GILEAD | Medical Information

Descovy for PrEP® (FTC/TAF) Clinical Practice Guidelines

This document is in response to your request for information regarding Descovy for PrEP® (emtricitabine/tenofovir alafenamide [FTC/TAF] for HIV-1 pre-exposure prophylaxis) and clinical practice guidelines.

This document includes content from, or references to clinical practice guidelines and should not be interpreted as a treatment recommendation or an endorsement of the guidelines by Gilead Sciences.

The use of FTC/TAF for prevention of HIV-1 in individuals at risk of HIV-1 from receptive vaginal sex is investigational and has not been approved by any regulatory authority. The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy_pi.

Clinical Practice Guidelines

Guidelines from the International Antiviral Society–USA (IAS-USA) panel on antiretroviral drugs for the prevention and treatment of HIV in adults can be accessed at: jamanetwork.com/journals/jama/fullarticle/2827545.

The IAS-USA panel published a brief update of its 2024 recommendations for the prevention of HIV following new data on the use of FTC/TAF among cisgender women, which can be accessed at: jamanetwork.com/journals/jama/fullarticle/2835835.

The Centers for Disease Control and Prevention clinical practice guidelines of PrEP for the prevention of HIV in the US can be accessed at: stacks.cdc.gov/view/cdc/159891.

Guidelines from the World Health Organization for HIV treatment and PrEP can be accessed at: www.who.int/publications/i/item/9789240031593.

The European AIDS Clinical Society produces guidelines for the management of treatment and prevention of HIV in Europe, which can be accessed at: www.eacsociety.org/guidelines/eacs-guidelines.

Product Label

For the full indication, important safety information, and boxed warning, please refer to the Descovy US Prescribing Information available at: www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy_pi.pdf.

Follow Up

For any additional questions, please contact Gilead Medical Information at:

☎1-866-MEDI-GSI (1-866-633-4474) or 🖱 www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or
🖱 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🖱 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact gilead.privacy@gilead.com.

DESCOVY, DESCOVY for PrEP, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
© 2026 Gilead Sciences, Inc.